Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function…
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on…
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to…
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3…
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer.…
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development…
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients…
- Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023…
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by…